Ambrosia Biosciences
Ambrosia Biosciences Announces the Nonclinical Data Profiles of Two Oral Small Molecule Programs: A GLP-1 Receptor Agonist Intended for Once-Weekly Dosing and a GIP Receptor Antagonist
AMB-895 and AMB-131 demonstrate highly differentiated PK profiles and robust efficacy in preclinical models The data were shared as poster…
